Anavex Life Sciences Corp (AVXL)

Anavex Life Sciences Corp. is a biopharmaceutical company focused on developing treatments for disorders of the central nervous system and other serious conditions. Its research pipeline includes programs for Alzheimer’s disease, Parkinson’s disease, schizophrenia, neurodevelopmental and neurodegenerative disorders, Rett syndrome, pain, and certain cancers. The company’s lead candidate, ANAVEX 2-73 (blarcamesine), is an orally available compound designed to help restore cellular balance through activity at SIGMAR1 and muscarinic receptors. It has been studied in multiple clinical programs, including trials in Alzheimer’s disease, Parkinson’s disease dementia, and Rett syndrome. Anavex also is advancing ANAVEX 3-71, a clinical-stage candidate targeting SIGMAR1 and M1 muscarinic receptors, with preclinical data in Alzheimer’s disease models. Founded in 2004, the company is headquartered in New York, New York.

Jump directly to the stock analysis sections supported by the latest available data.